Bristol-Myers Squibb
About: Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Employees: 34,100
0
Funds holding %
of 7,345 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
21% more first-time investments, than exits
New positions opened: 200 | Existing positions closed: 165
6% more capital invested
Capital invested by funds: $91.5B [Q4 2024] → $97.1B (+$5.67B) [Q1 2025]
2% more call options, than puts
Call options by funds: $1.73B | Put options by funds: $1.7B
0.14% less ownership
Funds ownership: 78.48% [Q4 2024] → 78.34% (-0.14%) [Q1 2025]
1% less funds holding
Funds holding: 2,450 [Q4 2024] → 2,437 (-13) [Q1 2025]
4% less repeat investments, than reductions
Existing positions increased: 936 | Existing positions reduced: 971
10% less funds holding in top 10
Funds holding in top 10: 39 [Q4 2024] → 35 (-4) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$34
29%
downside
Avg. target
$41
16%
downside
High target
$47
3%
downside
2 analyst ratings
0 positive
0%
1 neutral
50%
1 negative
50%
Citigroup Andrew Baum | 3%downside $47 | Neutral Maintained | 1 Aug 2025 |
Morgan Stanley Terence Flynn | 29%downside $34 | Underweight Maintained | 10 Jul 2025 |
Financial journalist opinion
Based on 61 articles about BMY published over the past 30 days
Positive
Seeking Alpha
1 day ago
Dividend Harvesting Portfolio Week 232: $23,200 Allocated, $2,467.76 In Projected Dividends
The Dividend Harvesting Portfolio rebounded strongly, with profitability up 8.06% and total dividend income now at 19.77% of invested capital. I remain bullish on the S&P 500 reaching 7,000 this year, driven by strong corporate earnings, AI productivity, and a likely lower rate environment. Recent additions to the portfolio—BMY, SLB, and AGNC—reflect my focus on undervalued, high-yield opportunities poised to benefit from rate cuts.
Positive
Zacks Investment Research
2 days ago
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.
Positive
The Motley Fool
2 days ago
Want Over $2,100 in Annual Dividends? Invest $12,000 Into Each of These 3 High-Yielding Stocks
Investing in high-yielding dividend stocks can result in significant dividend income for your portfolio. But higher yields also tend to mean higher risk, and dividends are never guaranteed.
Positive
Seeking Alpha
1 week ago
3 SWANs On Sale
Our focus for today includes BMY, REXR, and ELV. The trio offers a safe 4.2% dividend yield, an A- credit rating average, and a 27% weighted discount to fair value. Bristol-Myers Squibb possesses a lineup of blockbuster drugs and a solid pipeline of drugs, an A S&P credit rating, and offers a safe and sizable yield. Rexford Industrial Realty owns high-value, mission-critical real estate, pays a well-covered dividend, and has a BBB+ S&P credit rating.
Positive
Zacks Investment Research
1 week ago
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.
Positive
Morningstar
1 week ago
3 Dividend Stocks for August 2025
These three dividend payers have an average yield of 4.5%.
Positive
Zacks Investment Research
1 week ago
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Positive
Seeking Alpha
1 week ago
Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity
Bristol Myers Squibb is trading at a generational bargain, near 7x earnings, with a compelling 5.6% dividend yield and strong cash flow. Recent Q2 results beat expectations, and management is focused on growth initiatives, including AI-driven drug discovery and new partnerships. Despite near-term earnings declines, due to patent expirations, AI and pipeline opportunities offer potential upside not priced into the stock.
Neutral
Business Wire
1 week ago
Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb's Application for Breyanzi Accepted by U.S. FDA in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL).
Neutral
Seeking Alpha
1 week ago
Bristol-Myers Squibb: Buy The Weakness
Bristol-Myers Squibb faces political pressure on U.S. drug prices, but I see the risk as manageable given its strong fundamentals. The company's growth portfolio now exceeds half of revenue, offsetting legacy drug declines, and trades at a compelling single-digit P/E ratio. Robust cash flow supports a nearly 6% dividend yield and ongoing share repurchases, while debt remains manageable and on track for reduction.
Charts implemented using Lightweight Charts™